黑色素瘤中的双重免疫检查点抑制与 PD-L1 表达：尚无定论。

IF 42.1 1区医学 Q1 ONCOLOGY

Journal of Clinical Oncology Pub Date : 2025-01-10 Epub Date: 2024-10-07 DOI:10.1200/JCO-24-01572

Andreas Michael Schmitt, James Larkin, Sapna P Patel

引用次数: 0

摘要

这篇评论讨论了使用 PD-L1 作为生物标记物来指导转移性黑色素瘤的治疗决策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out.

This comment discusses the use of PD-L1 as a biomarker to guide treatment decisions for metastatic melanoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Clinical Oncology 医学-肿瘤学

CiteScore

41.20

自引率

2.20%

发文量

8215

审稿时长

2 months

期刊介绍： The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.